LEADER 05369nam 22006614a 450 001 9910143555503321 005 20170815170544.0 010 $a1-280-27583-9 010 $a9786610275830 010 $a0-470-24616-2 010 $a0-471-47876-8 010 $a0-471-47877-6 035 $a(CKB)1000000000355647 035 $a(EBL)231715 035 $a(OCoLC)475937996 035 $a(SSID)ssj0000221648 035 $a(PQKBManifestationID)11190880 035 $a(PQKBTitleCode)TC0000221648 035 $a(PQKBWorkID)10160754 035 $a(PQKB)10709615 035 $a(MiAaPQ)EBC231715 035 $a(EXLCZ)991000000000355647 100 $a20050223d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aPhysiologically based pharmacokinetic modeling$b[electronic resource] $escience and applications /$fedited by Micaela B. Reddy ... [et al.] 210 $aHoboken, N.J. $cWiley-Interscience$dc2005 215 $a1 online resource (442 p.) 300 $aDescription based upon print version of record. 311 $a0-471-47814-8 320 $aIncludes bibliographical references and index. 327 $aPHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; CONTENTS; PREFACE; ACKNOWLEDGMENTS; CONTRIBUTORS; CHAPTER 1 INTRODUCTION: A HISTORICAL PERSPECTIVE OF THE DEVELOPMENT AND APPLICATIONS OF PBPK MODELS; 1.1 Introduction; 1.2 A Historical Perspective; 1.2.1 Responses to Inhaled Compounds; 1.2.2 Pharmaceutical Applications; 1.2.3 Occupational and Environmental Applications; 1.2.4 Digital Computation and PBPK Modeling; 1.3 Expansion of PBPK Model Applications; 1.3.1 PBPK Models for Tissue Dosimetry from Secondary Data; 1.3.2 Biological Mechanisms Underlying Pharmacokinetic Behaviors 327 $a1.3.3 Chemicals as Probes of Biological Processes1.3.4 Risk Assessment Applications; 1.3.5 PBPK Models as Repository of Mechanistic Data on Distribution and Response; 1.4 Summary; Notation; References; PART I PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS; CHAPTER 2 HALOGENATED ALKANES; 2.1 Introduction; 2.2 PBPK Model Development for Volatile Organics; 2.2.1 Model Formulation; 2.2.2 Model Equations; 2.2.3 Model Parameterization; 2.2.4 Model Calculations; 2.3 Experimental Methods Demonstrated for Groups of Chemicals; 2.4 PBPK Models for Halogenated Alkanes; 2.4.1 Anesthetic Gases 327 $a2.4.2 Chlorofluorocarbons (CFCs), Refrigerants, and Halons2.4.3 Halogenated Alkanes; 2.5 Summary; Notation; References; CHAPTER 3 HALOGENATED ALKENES; 3.1 Introduction; 3.2 The Chloroethylenes: Background; 3.3 Review of PBPK Models; 3.3.1 Vinyl Chloride (VC); 3.3.2 Vinyl Fluoride (VF); 3.3.3 cis-1,2-Dichloroethylene (cDCE) and trans-1,2-Dichloroethylene (tDCE); 3.3.4 Vinylidene Chloride (VDC); 3.3.5 Trichloroethylene (TCE); 3.3.6 Tetrachloroethylene (PERC); 3.3.7 Allyl Chloride (AC); 3.3.8 b-Chloroprene (CD); 3.3.9 Hexachlorobutadiene, HCB; 3.4 Summary; Notation; References 327 $aCHAPTER 4 ALKENE AND AROMATIC COMPOUNDS4.1 Introduction; 4.2 PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds; 4.2.1 Metabolism and Mode of Action; 4.2.2 Model Structures; 4.2.3 PK Differences; 4.2.4 Extrahepatic Metabolism and Transport of Metabolites; 4.2.5 GSH Conjugation; 4.2.6 Endogenous Production; 4.2.7 Reactivity with DNA and Protein; 4.2.8 Inhibition of Second Oxidative Steps; 4.2.9 Variability and PK Differences; 4.2.10 Subcompartments in PBPK Models; 4.2.11 "Privileged Access" of Epoxide Hydratase to Epoxide Substrates 327 $a4.3 Review of Aromatic and Alkene PBPK Models4.3.1 Benzene-A Known Human Carcinogen with an Uncertain Mode of Action; 4.3.2 Styrene-Early PBPK Models; 4.3.3 1,3-Butadiene; 4.3.4 Isoprene; 4.3.5 Ethylene, Propylene, and Their Oxides; 4.3.6 Naphthalene and Other PAHs; 4.3.7 Halobenzenes; 4.3.8 Miscellaneous Related Compounds; 4.4 Summary; Notation; References; CHAPTER 5 REACTIVE VAPORS IN THE NASAL CAVITY; 5.1 Introduction; 5.1.1 Nasal Effects and Risk Assessment; 5.1.2 General Models for Nasal Uptake; 5.2 No Air-Phase Models; 5.2.1 The "Perfused Nose" Model; 5.2.2 Vinyl Acetate 327 $a5.3 Creating the Air-Phase Compartments 330 $aA definitive, single source of information on PBPK modelingPhysiologically-based pharmacokinetic (PBPK) modeling is becoming increasingly important in human health risk assessments and in supporting pharmacodynamic modeling for toxic responses. Organized by classes of compounds and modeling purposes so users can quickly access information, this is the first comprehensive reference of its kind.This book presents an overview of the underlying principles of PBPK model development. Then it provides a compendium of PBPK modeling information, including historical development, specific modeli 606 $aPharmacokinetics 606 $aXenobiotics 606 $aToxicology 608 $aElectronic books. 615 0$aPharmacokinetics. 615 0$aXenobiotics. 615 0$aToxicology. 676 $a615.7040724 676 $a615/.7 701 $aReddy$b Micaela B$0981316 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910143555503321 996 $aPhysiologically based pharmacokinetic modeling$92239855 997 $aUNINA